MELD—good for many, not as good for others … at least for now

Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464–470 Bernardi M, Gitto S, Biselli M. The MELD score in patients awaiting liver transplant: strengths and weaknesses. J Hepatol 2011;54:1297–1306 Bambha K, Kim WR, Kremers WK, et al. Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements. Am J Transplant 2004;4:1798–1804 Brown RS Jr, Higgins R, Pruett TL. The evolution and direction of OPTN oversight of live organ donation and transplantation in the United States. Am J Transplant 2009;9:31–34 Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology 2006;127:S261–S267 Sharma P, Harper AM, Hernandez JL, et al. Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation. Am J Transplant 2006;6:1957–1962 Massie AB, Caffo B, Gentry SE, et al. MELD exceptions and rates of waiting list outcomes. Am J Transplant 2011;11(11):2362–2371 Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008;359:1018–1026 Rosen CB, Heimbach JK, Gores GJ. Liver transplantation for cholangiocarcinoma. Transpl Int 2010;23:692–697 Jacob M, Copley LP, Lewsey JD, et al. Pretransplant MELD score and post liver transplantation survival in the UK and Ireland. Liver Transpl 2004;10:903–907 Tenório AL, Macedo FI, Miranda LE, et al. Survival on waiting list for liver transplantation before and after introduction of the model for end-stage liver disease score. Transplant Proc 2010;42:407–411 Foxton MR, Al-Freah MA, Portal AJ, et al. Increased model for end-stage liver disease score at the time of liver transplant results in prolonged hospitalization and overall intensive care unit costs. Liver Transpl 2010;16:668–677 McCormack L, Gadano A, Lendoire J, et al. Model for end-stage liver disease-based allocation system for liver transplantation in Argentina: does it work outside the United States? HPB (Oxford) 2010;12:456–464 Westbrook RH, Yeoman AD, O’Grady JG, et al. Model for end-stage liver disease score predicts outcome in cirrhotic patients during pregnancy. Clin Gastroenterol Hepatol 2011;9:694–699 Inaba K, Barmparas G, Resnick S, et al. The model for end-stage liver disease score: an independent prognostic factor of mortality in injured cirrhotic patients. Arch Surg 2011;146:1074–1078 Cho HC, Jung HY, Sinn DH, et al. Mortality after surgery in patients with liver cirrhosis: comparison of Child–Turcotte–Pugh, MELD and MELDNa score. Eur J Gastroenterol Hepatol 2011;23:51–59 Yantorno SE, Kremers WK, Ruf AE, et al. MELD is superior to King’s college and Clichy’s criteria to assess prognosis in fulminant hepatic failure. Liver Transpl 2007;13:822–828 Srikureja W, Kyulo NL, Runyon BA, et al. MELD score is a better prognostic model than Child–Turcotte–Pugh score or discriminant function score in patients with alcoholic hepatitis. J Hepatol 2005;42:700–706 Kim JD, Choi JY, Kwon JH, et al. Performance of posttransplant model for end-stage liver disease (MELD) and delta-MELD scores on short-term outcome after living donor liver transplantation. Transplant Proc 2009;41:3766–3768 Northup PG, Berg CL. Preoperative delta-MELD score does not independently predict mortality after liver transplantation. Am J Transplant 2004;4:1643–1649 Al-Freah MAB, et al. The effect of changes of model for end-stage liver disease score during waiting time on post-liver transplant mortality. Hepatol Int 2012;6:491–497 Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant 2008;8:1982–1989 Pomfret EA, Washburn K, Wald C, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010;16:262–278